• Users Online: 104
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 11  |  Issue : 2  |  Page : 80-83

Serum levels of interleukin-17 in patients with and without acute coronary syndrome: A cross-sectional study in Babol, Northern Iran

1 Department of Cardiovascular Diseases, Babol University of Medical Sciences, Babol, Iran
2 Student Research Committee; Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran
3 Cellular and Molecular Biology Research Center; Department of Immunology, Babol University of Medical Sciences, Babol, Iran
4 Student Research Committee, Babol University of Medical Sciences, Babol, Iran

Correspondence Address:
Mehrdad Saravi
Ayatollah Roohani Hospital, Babol University of Medical Sciences, Ganjafruz Street, Babol
Login to access the Email id

Source of Support: The Deputy of Research of Babol University of Medical Sciences for the financial support, Conflict of Interest: None

DOI: 10.4103/0189-7969.142086

Rights and Permissions

Background: The role of interleukin-17 (IL-17) in patients with acute coronary syndrome (ACS) is controversial. Objective: The aim of this study was to assess the serum level of IL-17 in patients with acute myocardial infarction (AMI) and unstable angina (UA) in Babol, Northern Iran in 2012. Materials and Methods: A total of 60 patients with ACS (30 with AMI, 30 with UA) and 30 healthy blood donors of Babol city, Iran were recruited in this cross-sectional study. Simple sampling method was used for patient selection. The inclusion criteria were the recent (<48 h) diagnosis of AMI or UA. The exclusion criteria were: Diagnosis of AMI or UA >48 h, recent history of infection or use of antibiotics. The serum IL-17 level was measured using enzyme-linked immunosorbent assay kit (Bioscience, Texas, USA). The lowest concentration of IL-17 that the kit could detect was 0.8 pg/ml. Chi-square, and Kruskal-Wallis tests were used for the comparison of IL-17 level between participants. P < 0.05 was considered as significant. Results: A total of 10 participants were excluded due to contaminated blood samples. Fifty (62.5%) were males and 30 (37.5%) were females. Four (13.3%) patients of AMI group and 1 (3.3%) of UA group had detectable levels of IL-17 (P = 0.353), but no one in blood donors (P = 0.114). There was also no significant association between the presence of detectable level of IL-17 and history of diabetes mellitus, hypertension, hyperlipidemia, smoking (P > 0.05). Conclusion: Our study did not find any significant differences in the serum level of IL-17 in individuals with or without ACS and therefore did not support the theory in which IL-17 has deleterious role in atherosclerosis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded270    
    Comments [Add]    

Recommend this journal